Thibault Géoui

Frankfurt · Life sciences × AI

The real constraint in pharma R&D isn't the science. It's knowledge flow.

I'm Thibault Géoui, a structural biologist turned life sciences and technology leader. I write about AI in drug R&D, host the Tech & Drugs podcast, and think about how knowledge moves inside the organisations trying to cure disease.

Read the writing Listen to the podcast
Thibault Géoui

About me

I'm a life sciences and biotech leader with two decades of experience turning complex science into scalable, industry-ready solutions. My career spans product management (SaaS, DaaS), sales and marketing, strategy, digital transformation, and AI-driven innovation across QIAGEN, Elsevier, Charles River Laboratories, and Zühlke.

I've led more than 30 product introductions, repositioned core scientific platforms, and built data and AI strategies that accelerate discovery. At Charles River I shaped a modern analytics and product vision; at Zühlke I now drive the go-to-market for Pharma R&D, bridging engineering excellence with the realities of drug development.

I hold a PhD in structural biology, and the through-line in everything I do is the same: AI's value in pharma depends on solving coordination, knowledge flow, and institutional memory before scaling automation. I host the Tech & Drugs podcast, exploring how AI, automation, and data are reshaping pharma and biotech, and I rank among the top 1% of industry voices on LinkedIn.

If you're working at the junction of science and technology, or trying to get there, I'm always open to a conversation. I like connecting worlds that rarely talk to each other, and seeing what happens when they finally do.

Writing

Long-form essays and articles on AI, drug discovery, and the economics of scientific knowledge. I post less often but longer.

Most read

How to 10x Pharma

Coordination, flow, and people are the binding constraint in drug R&D. Not the science.

 Most read

Beyond the Safety Lens

Pharma is organised around AI safety. The prior discipline it actually needs is scientific alignment.

 Most read

The Translator's Dilemma

What four years and 3,400 LinkedIn posts taught me about translating between biology and technology.
All articles on LinkedIn →

Tech & Drugs

Conversations with the people rewiring pharma: C-suite and VP-level leaders on what it actually takes to make AI work in drug R&D. No hype, no vendor pitches, just the operating reality.

Spotify Apple Podcasts YouTube
  • Thomas Steger-Hartmann Bayer · VICTOR Consortium

    Can AI end animal testing? The state of computational toxicology.

  • Laura Matz Chief Science & Technology Officer, Merck KGaA

    Running science and technology as one function.

  • Sabya DasGupta Global VP R&D Data Platforms, Sanofi

    The brain of the lab needs a body: fixing the unglamorous foundations first.

Books

Three books in progress, at very different stages. The long form is where I am most at home.

i

The method behind the voice

Four years, ~3,400 posts, and 89 articles distilled into a book on building a real voice online, built around the method I use: Collect, Create, Distribute. Written for two readers: the individual who wants genuine peers rather than an audience, and the leader who suspects a few people inside their organisation could reshape how it reaches the world.

Nearly finished
ii

10x Pharma

The book the writing and the podcast have been building toward: how AI is changing science, and what a genuine order-of-magnitude gain in R&D productivity would take. The argument in one line: the binding constraint is not the science, it is coordination, flow, and the institutional brain that holds what everyone forgets.

In progress
iii

The strange one

Political science fiction. 1984 rewritten for an age of frontier labs and humanoid robots on eight-hour shifts. Orwell meets Asimov. Early days, and the one I am most excited about.

Early stage

Venabili Labs

Selected independent projects

Venabili Labs is my independent practice, where I help executives and teams in life sciences refine their message, amplify their visibility, and articulate thought leadership that genuinely resonates. Think scientific communication, positioning, and the writing that turns deep expertise into a voice people actually follow.

These are personal engagements, deliberately limited in number, and distinct from the consulting and delivery work clients come to Zühlke for. If you're building something ambitious at the junction of science and technology, or want help finding the words for it, I'd like to hear about it.

Get in touch